Vaccine-preventable diseases in Europe: Where do we stand?

Expert Review of Vaccines

Volumn 13, Issue 8, 2014, Pages 979-987

  Wicker, Sabine ^a   Maltezou, Helena C ^b  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b Hellenic Center for Disease Control and Prevention   (Greece)

Author keywords

Control; Eradication; Europe; Immunization; Outbreaks; Re emergence; Vaccination; Vaccine preventable diseases

Indexed keywords

VACCINE;

COMMUNICABLE DISEASES; EUROPE; HUMAN; IMMUNOLOGY; UTILIZATION; VACCINATION;

COMMUNICABLE DISEASES; EUROPE; HUMANS; VACCINATION; VACCINES;

EID: 84904324113     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2014.933077     Document Type: Review

References (76)

1. van Panhuis WG, Grefenstette J, Jung SY, et al. Contagious diseases in the United States from 1888 to the present. N Engl J Med 2013;369: 2152-8 •• Comprehensive description of epidemiology of vaccine-preventable diseases before and after widespread implementation of vaccinations.
2. Centers for Disease Control and Prevention (CDC). Ten great public health achievements - Worldwide, 2001-2010. MMWR 2011;60: 814-13
3. Roush SW, Murphy TV; Vaccine-Preventable Disease Table Working Group. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA 2007;298: 2155-63 •• Comprehensive description of epidemiology of vaccine-preventable diseases before and after widespread implementation of vaccinations.
4. Council on Foreign Relations. Global Health Program interactive map vividly illustrates the increase in certain vaccine-preventable diseases. Available from: www.cfr.org/interactives/GH-Vaccine-Map/#/intro [Last accessed 1 April 2014] • Interactive map which illustrates visually global outbreaks of measles, mumps, whooping cough, polio, rubella and other vaccine-preventable diseases (VPDs).
5. Kramarz P, Lopalco PL, Huitric E, et al. Vaccine-preventable diseases. The role of the European centre for disease prevention and control. Clin Microbiol Infect 2014; 20(Suppl 5): 2-6
6. UNICEF. 2013 Statistical snapshot child mortality. Available from: www.childinfo. org/files/Child-Mortality-Stat-Snapshot-eversion- Sep-17.pdf [Last accessed 1 April 2014]
7. Zepp F, Heininger U, Mertsola J, et al. Rationale for pertussis booster vaccination throughout life in Europe. Lancet Infect Dis 2011;11: 557-70
8. Martin R, Jankovic D, Goel A, et al. Increased transmission and outbreaks of measles - European region, 2011. MMWR 2011;47: 1605-10
9. Larson HJ, Paterson P. Eradicating polio: persisting challenges beyond endemic countries. Expert Rev Vaccines 2011;10: 1635-6
10. Wassilak S, Orenstein W. Challenges faced by the global polio eradication initiative. Expert Rev Vaccines 2010;9: 447-9
11. Park YJ, Eom HS, Kim ES, et al. Reemergence of measles in South Korea: implications for immunization and surveillance programs. Jpn J Infect Dis 2013;66: 6-10
12. Venice. Vaccine European new integrated collaboration effort. Available from: http://venice.cineca.org [Last accessed 1 April 2014]
13. Lopalco PL, Carrillo Santisteve P. Actual immunization coverage throughout Europe: are existing data sufficient? Clin Microbiol Infect 2014;20(Suppl 5): 7-11
14. WHO/UNICEF. Estimates of national immunization coverage. Available from: www.who.int/immunization-monitoring/routine/immunization-coverage/en/index4. html [Last accessed 1 April 2014]
15. World Health Organization (WHO), UNICEF. Global immunization data. Available from: www.who.int/immunization/monitoring-surveillance/Global- Immunization-Data.pdf?ua=1 [Last accessed 1 April 2014]
16. European Centre for Disease Prevention and Control (ECDC). Surveillance report: measles and rubella monitoring. Available from: www.ecdc.europa.eu/en/ publications/Publications/measles-rubella-surveillance-oct- 2013.pdf [Last accessed 1 April 2014]
17. Muscat M, Shefer A, Ben Mamou M, et al. The state of measles and rubella in the WHO European Region, 2013. Clin Microbiol Infect 2014;20(Suppl 5): 12-18
18. Public Health England. Confirmed cases of measles, mumps and rubella 1996-2012. Available from: www.hpa.org.uk/web/HPAweb&HPAwebStandard/HPAweb- C/1195733833790 [Last accessed 1 April 2014]
19. Poland GA, Jacobson RM. The re-emergence of measles in developed countries: time to develop the next-generation measles vaccines? Vaccine 2012;30: 103-4
20. Poland GA. MMR vaccine and autism: vaccine nihilism and postmodern science. Mayo Clin Proc 2011;86: 869-71
21. Poland GA, Spier R. Fear, misinformation, and innumerates: how the Wakefield paper, the press, and advocacy groups damaged the public health. Vaccine 2010;28: 2361-2
22. European Centre for Disease Prevention and Control (ECDC). Surveillance report: annual epidemiological report - Reporting on 2011 surveillance data and 2012 epidemic intelligence data. Available from: www.ecdc.europa.eu [Last accessed 1 April 2014]
23. Robert Koch-Institute SurvStat. Measles cases in Germany. Available from: www3. rki.de/SurvStat [Last accessed 1 April 2014]
24. Muscat M. Who gets measles in Europe? J Infect Dis 2011(Suppl 1):S353-65 • Comprehensive description of regional measles epidemiology and elimination goals.
25. Muscat M, Bang H, Wohlfahrt J, et al. Measles in Europe: an epidemiological assessment. Lancet 2009;373: 383-9
26. World Health Organization Europe (WHO). WHO Epi Data. Available from: www.euro.who.int/--data/assets/pdf-file/0020/243641/EpiData12-2013.pdf [Last accessed 1 April 2014]
27. Maltezou HC, Wicker S. Measles in healthcare settings. Am J Infect Control 2013;41: 661-3
28. Rubin SA, Plotkin SA. Mumps vaccine. In: Plotkin SA, Orenstein WA, Offit PA, Vaccines. 6th Edition. 2013. p. 427-9
29. Takla A, Böhmer MM, Klinc C, et al. Outbreak-related mumps vaccine effectiveness among a cohort of children and of young adults in Germany 2011. Hum Vaccin Immunother 2014;10(1): 140: 5
30. Calvert N, Ashton JR, Garnett E. Mumps outbreak in private schools: public health lessons for the post-Wakefield era. Lancet 2013;381: 1625-6
31. Lexová P, Limberková R, Cástková J, Kyncl J. Increased incidence of mumps in the Czech Republic in the years 2011 and 2012. Acta Virol 2013;57: 347-51
32. Greenland K, Whelan J, Fanoy E, et al. Mumps outbreak among vaccinated university students associated with a large party, the Netherlands, 2010. Vaccine 2012;30: 4676-80
33. Barskey AE, Schulte C, Rosen JB, et al. Mumps outbreak in Orthodox Jewish communities in the United States. N Engl J Med 2012;367: 1704-13
34. Peltola H, Davidkin I, Paunio M, et al. Mumps and rubella elimated from Finland. JAMA 2000;284: 2643-7
35. Choi KM. Reemergence of mumps. Korean J Pediatr 2010;54: 623-8
36. Davidkin I, Kontio M, Paunio M, Peltola H. MMR vaccination and disease elimination: the Finnish experience. Expert Rev Vaccines 2010;9: 1045-53
37. Reef SE, Plotkin SA. Rubella vaccine. In: Plotkin SA, Orenstein WA, Offit PA, Vaccines. 6th Edition. 2013. p. 688-717
38. World Health Organization (WHO). WHO vaccine-preventable disease monitoring system, 2013 global summary. Available from: http://apps.who.int/ immunization-monitoring/globalsummary [Last accessed 1 April 1, 2014]
39. Wagner KS, White JM, Lucenko I, et al. Diphtheria in the postepidemic period, Europe, 2000-2009. Emerg Infect Dis 2012;18: 217-25
40. Zakikhany K, Efstratiou A. Diphtheria in Europe: current problems and new challenges. Future Microbiol 2012;7: 595-607
41. Edmunds WJ, Pebody RG, Aggerback H, et al. The sero-epidemiology of diphtheria in Western Europe. ESEN Project. European sero-epidemiology network. Epidemiol Infect 2000;125: 113-25
42. Markina SS, Maksimova NM, Vitek CR, et al. Diphtheria in the Russian Federation in the 1990s. J Infect Dis 2000; 181(Suppl 1):S27-34
43. Miller BL, Ahmed F, Lindley MC, Wortley PM. Increases in vaccination coverage of healthcare personnel following institutional requirements for influenza vaccination: a national survey of U.S. hospitals. Vaccine 2011;29: 9398-403
44. Lu PJ, Graitcer SB, O'Halloran A, Liang JL. Tetanus, diphtheria and acellular pertussis (Tdap) vaccination among healthcare personnel - United States, 2011. Vaccine 2014;32: 572-8
45. Di Giovine P, Kafatos G, Nardone A, et al. Comparative seroepidemiology of diphtheria in six European countries and Israel. Epidemiol Infect 2013;141: 132-42
46. Poland GA, Belmin J, Langley J, et al. A global prescription for adult immunization: time is catching up with us. Vaccine 2010;28: 7137-9
47. Mills KH, Gerdts V. Mouse and pig models for studies of natural and vaccine-induced immunity to Bordetella pertussis. J Infect Dis 2014;209(Suppl 1):S16-19
48. Cherry JD. Epidemic pertussis in 2012 - The resurgence of a vaccinepreventable disease. N Engl J Med 2012;367: 785-7
49. Libster R, Edwards KM. Re-emergence of pertussis: what are the solutions? Expert Rev Vaccines 2012;11: 1331-46
50. Plotkin SA. The pertussis problem. Clin Infect Dis 2014;58(6): 830-3
51. Black RE, Cousens S, Johnson HL, et al. Global, regional and national causes of child mortality in 2008: a systematic analysis. Lancet 2010;375: 1969-87
52. Guiso N. Bordetella pertussis: why is it still circulating? J Infect 2014;68:S119-24
53. Guiso N, Liese J, Plotkin S. The Global Pertussis initiative. meeting report from the fourth regional roundtable meeting, France, April 14-15, 2010. Human Vaccines 2011;7: 481-8
54. CDC. Tdap for pregnant women: information for providers. Available from: www.cdc.gov/vaccines/vpd-vac/pertussis/tdap-pregnancy-hcp.htm [Last accessed 16 May 2014]
55. van der Ark AAJ, Hozbor DF, Boog CJP, et al. Resurgence of pertussis calls for re-evaluation of pertussis animal models. Expert Rev Vaccines 2012;1: 1121-37
56. Thompson KM, Radboud J, Tebbens D. Current polio global eradication and control policy options: perspectives from modeling and perquisites for oral poliovirus vaccine cessation. Expert Rev Vaccines 2012;11: 449-59
57. Pliaka V, Kyriakopoulou Z, Markoulatos P. Risks associated with the use of live-attenuated vaccine poliovirus strains and the strategies for control and eradication of paralytic poliomyelitis. Expert Rev Vaccines 2012;11: 609-28
58. European Centre for Disease Prevention and Control (ECDC). Updated ECDC risk assessment on the risk of wild poliovirus importation and transmission in EU/EEA countries. Available from: www.ecdc. europa.eu/en/press/news/-layouts/ forms/News-DispForm.aspx?List=8db7286c% 2Dfe2d%2D476c%2D9133% 2D18ff4cb1b568&ID=923&Web= 86661a14%2Dfb61%2D43e0%2D9663% 2D0d514841605d [Last accessed 1 April 2014]
59. Centers for Disease Control and Prevention (CDC). Updates on CDC's polio eradication efforts. Available from: www. cdc.gov/polio/updates/index.htm [Last accessed 19 May 2014]
60. UNICEF, WHO. Syrian Arab Republic, situation report No 11. Available from: www.emro.who.int/images/stories/syria/documents/Syrian-Arab-Republic- Polio- Sitreport-No-11.pdf. [Last accessed 1 April 2014]
61. Celentano LP, Lopalco PL, Huitric E, et al. Polio and the risk for the European Union. Lancet 2014;383: 216-17
62. Cooper LZ, Larson HJ, Katz SL. Protecting public trust in immunization. Pediatrics 2008;122: 149-53
63. Larson HJ. Negotiating vaccine acceptance in an era of reluctance. Hum Vaccin Immunother 2013;9: 1779-81
64. Larson HJ, Cooper LZ, Eskola J, et al. Addressing the vaccine confidence gap. Lancet 2011;378: 526-35 •• Comprehensive description of psychological factors which determine the vaccination behavior.
65. Wheelock A, Thomson A, Sedalis N. Social and psychological factors underlying adult vaccination behavior: lessons from seasonal influenza vaccination in the US and the UK. Expert Rev Vaccines 2013;12(8): 893-901
66. Wicker S, Rabenau HF, von Gierke L, et al. Hepatitis B and influenza vaccines: important occupational vaccines differently perceived among medical students. Vaccine 2013;31: 5111-17
67. Johnson DR, Nichol Kl, Lipczynski K. Barriers to adult immunization. Am J Med 2008;121:S28-35
68. Wadl M, Siedler A, Krämer W, et al. Measles transmission from an anthroposophic community to the general population, Germany 2008. BMC Public Health 2011;11: 474
69. Ernst E. Does anthroposophic medicine cause measles outbreaks. Dtsch Med Wochenschr 2011;136: 2271-2
70. Grabenstein JD. What the World's religions teach, applied to vaccines and immune globulins. Vaccine 2013;31: 2011-23
71. Bulletin of the World Health Organization. Underlying issues are key to dispelling vaccine doubts. Available from: www.who. int/bulletin/volumes/92/2/ 14-030214/en/[Last accessed 1 April 2014]
72. Poland GA, Jacobson RM. The age-old struggle against antivaccinationists. N Engl J Med 2011;364: 97-9
73. Haverkate M, D'Ancona F, Johansen K, et al. Assessing vaccination coverage in the EU: Is it still a challenge? Expert Rev Vaccines 2011;10: 1195-205
74. Cutts FT, Lessler J, Metcalf CJE. Measles elimination: progress, challenges and implications for rubella control. Expert Rev Vaccines 2013;12: 917-32 •• Comprehensive description of regional progress toward measles and rubella control and elimination goals.
75. Maltezou HC, Wicker S, Borg M, et al. Vaccination policies for health-care workers in acute health-care facilities in Europe. Vaccine 2011;29: 9557-62
76. Maltezou HC, Tsakris A. Vaccination of health-care workers against influenza: our obligation to protect patients. Influenza Other Respir Viruses 2011;5: 382-8